Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3

Neuroscience

Volumn 339, Issue , 2016, Pages 191-209

  Rodríguez Cueto, Carmen ^a,b,c   Hernández Gálvez, Mariluz ^a,b,c   Hillard, Cecilia J ^d   Maciel, Patricia ^e,f   García García, Luis ^a,g   Valdeolivas, Sara ^a,b,c   Pozo, Miguel A ^a   Ramos, José A ^a,b,c   Gómez Ruiz, María ^a,b,c   Fernández Ruiz, Javier ^a,b,c  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e UNIVERSITY OF MINHO   (Portugal)

^f UNIVERSITY OF MINHO   (Portugal)

^g UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

autosomal dominant inherited ataxias; cannabinoids; endocannabinoid signaling system; Machado Joseph disease; motor incoordination; spinocerebellar ataxia 3

Indexed keywords

ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; EXCITATORY AMINO ACID TRANSPORTER; EXCITATORY AMINO ACID TRANSPORTER 1; FATTY ACID AMIDASE; GLUTAMATE TRANSPORTER; LIPID; N OLEOYLETHANOLAMINE; NEURON SPECIFIC ENOLASE; TUMOR NECROSIS FACTOR; AMIDASE; CNR1 PROTEIN, MOUSE; CNR2 PROTEIN, MOUSE; FATTY-ACID AMIDE HYDROLASE; GLUCOSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN STEM; CELL STRUCTURE; CEREBELLUM; CONTROLLED STUDY; DENTATE NUCLEUS; DISEASE COURSE; DYSTONIA; GAIT DISORDER; GLUCOSE METABOLISM; IN VIVO STUDY; MALE; MOTOR COORDINATION; MOUSE; MUSCLE WEAKNESS; NONHUMAN; PHENOTYPE; PONTINE NUCLEUS; PRIORITY JOURNAL; PURKINJE CELL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPINOCEREBELLAR ATAXIA TYPE 3; SPINOCEREBELLAR DEGENERATION; TRANSGENIC MOUSE; WESTERN BLOTTING; ANIMAL; DIAGNOSTIC IMAGING; DISEASE MODEL; GLIA; MACHADO JOSEPH DISEASE; METABOLISM; MOTOR ACTIVITY; NERVE CELL; PATHOLOGY; PHYSIOLOGY;

AMIDOHYDROLASES; ANIMALS; BRAIN STEM; CEREBELLUM; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; GLUCOSE; MACHADO-JOSEPH DISEASE; MICE, TRANSGENIC; MOTOR ACTIVITY; NEUROGLIA; NEURONS; PHENOTYPE; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 84992735493     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2016.09.046     Document Type: Article

References (51)

1. Alves, S., Nascimento-Ferreira, I., Dufour, N., Hassig, R., Auregan, G., Nóbrega, C., et al. Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3?. Hum Mol Genet 19 (2010), 2380–2394.
2. Blankman, J.L., Long, J.Z., Trauger, S.A., Siuzdak, G., Cravatt, B.F., ABHD12 controls brain lysophosphatidylserine pathways that are deregulated in a murine model of the neurodegenerative disease PHARC. Proc Natl Acad Sci USA 110 (2013), 1500–1505.
3. Chen, D.H., Naydenov, A., Blankman, J.L., Mefford, H.C., Davis, M., Sul, Y., et al. Two novel mutations in ABHD12: expansion of the mutation spectrum in PHARC and assessment of their functional effects. Hum Mutat 34 (2013), 1672–1678.
4. Chou, A.H., Chen, S.Y., Yeh, T.H., Weng, Y.H., Wang, H.L., HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3. Neurobiol Dis 41 (2011), 481–488.
5. Chou, A.H., Yeh, T.H., Ouyang, P., Chen, Y.L., Chen, S.Y., Wang, H.L., Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation. Neurobiol Dis 31 (2008), 89–101.
6. Cristino, L., de Petrocellis, L., Pryce, G., Baker, D., Guglielmotti, V., Di Marzo, V., Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 139 (2006), 1405–1415.
7. Deleye, S., Verhaeghe, J., wyffels, L., Dedeurwaerdere, S., Stroobants, S., Staelens, S., Towards a reproducible protocol for repetitive and semi-quantitative rat brain imaging with (18) F-FDG: exemplified in a memantine pharmacological challenge. Neuroimage 96 (2014), 276–287.
8. DeSanty, K.P., Dar, M.S., Cannabinoid-induced motor incoordination through the cerebellar CB1 receptor in mice. Pharmacol Biochem Behav 69 (2001), 251–259.
9. Di Marzo, V., Stella, N., Zimmer, A., Endocannabinoid signalling and the deteriorating brain. Nat Rev Neurosci 16 (2015), 30–42.
10. Durr, A., Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol 9 (2010), 885–894.
11. Evert, B.O., Vogt, I.R., Vieira-Saecker, A.M., Ozimek, L., de Vos, R.A., Brunt, E.R., et al. Gene expression profiling in ataxin-3 expressing cell lines reveals distinct effects of normal and mutant ataxin-3. J Neuropathol Exp Neurol 62 (2003), 1006–1018.
12. Evert, B.O., Schelhaas, J., Fleischer, H., de Vos, R.A., Brunt, E.R., Stenzel, W., et al. Neuronal intranuclear inclusions, dysregulation of cytokine expression and cell death in spinocerebellar ataxia type 3. Clin Neuropathol 25 (2006), 272–281.
13. Fernández-Ruiz, J., García, C., Sagredo, O., Gómez-Ruiz, M., de Lago, E., The endocannabinoid system as a target for the treatment of neuronal damage. Expert Opin Ther Targets 14 (2010), 387–404.
14. Fernández-Ruiz, J., Moreno-Martet, M., Rodríguez-Cueto, C., Palomo-Garo, C., Gómez-Cañas, M., Valdeolivas, S., et al. Prospects for cannabinoid therapies in basal ganglia disorders. Br J Pharmacol 163 (2011), 1365–1378.
15. Fernández-Ruiz, J., Moro, M.A., Martínez-Orgado, J., Cannabinoids in neurodegenerative disorders and stroke/brain trauma: from preclinical models to clinical applications. Neurotherapeutics 12 (2015), 793–806.
16. Fernández-Ruiz, J., Romero, J., Velasco, G., Tolón, R.M., Ramos, J.A., Guzmán, M., Cannabinoid CB2 receptor: a new target for controlling neural cell survival?. Trends Pharmacol Sci 28 (2007), 39–45.
17. Fernández-Ruiz, J., Sagredo, O., Pazos, M.R., García, M.C., Pertwee, R.G., Mechoulam, R., et al. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?. Br J Clin Pharmacol 75 (2013), 323–333.
18. Fiskerstrand, T., H'mida-Ben Brahim, D., Johansson, S., M'zahem, A., Haukanes, B.I., Drouot, N., et al. Mutations in ABHD12 cause the neurodegenerative disease PHARC: An inborn error of endocannabinoid metabolism. Am J Hum Genet 87 (2010), 410–417.
19. Fratkin, J.D., Vig, P.J., Neuropathology of degenerative ataxias. Handb Clin Neurol 103 (2012), 111–125.
20. Gould, V.F.C., Mouse models of spinocerebellar ataxia type 3 (Machado-Joseph disease). Neurotherapeutics 9 (2012), 285–296.
21. He, F., Kumar, A., Song, Z.H., Heat shock protein 90 is an essential molecular chaperone for CB2 cannabinoid receptor-mediated signaling in trabecular meshwork cells. Mol Vis 18 (2012), 2839–2846.
22. Ishikawa, K., Mizusawa, H., Fujita, T., Ohkoshi, N., Doi, M., Komatsuzaki, Y., et al. Calbindin-D 28k immunoreactivity in the cerebellum of spinocerebellar degeneration. J Neurol Sci 129 (1995), 179–185.
23. Jacobi, H., Reetz, K., du Montcel, S.T., Bauer, P., Mariotti, C., Nanetti, L., et al. Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data. Lancet Neurol 12 (2013), 650–658.
24. Klockgether, T., Update on degenerative ataxias. Curr Opin Neurol 24 (2011), 339–345.
25. Koeppen, A.H., The pathogenesis of spinocerebellar ataxia. Cerebellum 4 (2005), 62–73.
26. Koeppen, A.H., Ramirez, R.L., Bjork, S.T., Bauer, P., Feustel, P.J., The reciprocal cerebellar circuitry in human hereditary ataxia. Cerebellum 12 (2013), 493–503.
27. Matilla-Dueñas, A., Machado-Joseph disease and other rare spinocerebellar ataxias. Adv Exp Med Biol 724 (2012), 172–188.
28. Matilla-Dueñas, A., Corral-Juan, M., Volpini, V., Sánchez, I., The spinocerebellar ataxias: clinical aspects and molecular genetics. Adv Exp Med Biol 724 (2012), 351–374.
29. Menzies, F.M., Huebener, J., Renna, M., Bonin, M., Riess, O., Rubinsztein, D.C., Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3. Brain 133 (2010), 93–104.
30. Murata, Y., Yamaguchi, S., Kawakami, H., Imon, Y., Maruyama, H., Sakai, T., et al. Characteristic magnetic resonance imaging findings in Machado-Joseph disease. Arch Neurol 55 (1998), 33–37.
31. Nascimento-Ferreira, I., Nóbrega, C., Vasconcelos-Ferreira, A., Onofre, I., Albuquerque, D., Aveleira, C., et al. Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machado-Joseph disease. Brain 136 (2013), 2173–2188.
32. Nogami, M., Takatsu, A., Endo, N., Ishiyama, I., Immunohistochemistry of neuron-specific enolase in neurons of the medulla oblongata from human autopsies. Acta Histochem 100 (1998), 371–382.
33. Orr, H.T., Cell biology of spinocerebellar ataxia. J Cell Biol 197 (2012), 167–177.
34. Patel, S., Hillard, C.J., Cannabinoid CB1 receptor agonists produce cerebellar dysfunction in mice. J Pharmacol Exp Ther 297 (2001), 629–637.
35. Patel, S., Wohlfeil, E.R., Rademacher, D.J., Carrier, E.J., Perry, L.J., Kundu, A., et al. The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol 139 (2003), 1005–1013.
36. Paulson, H.L., Perez, M.K., Trottier, Y., Trojanowski, J.Q., Subramony, S.H., Das, S.S., et al. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 19 (1997), 333–344.
37. Paulson, H., Machado-Joseph disease/spinocerebellar ataxia type 3. Handb Clin Neurol 103 (2012), 437–449.
38. Riess, O., Rüb, U., Pastore, A., Bauer, P., Schöls, L., SCA3: neurological features, pathogenesis and animal models. Cerebellum 7 (2008), 125–137.
39. 2 receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias. Brit J Pharmacol 171 (2014), 1472–1489.
40. Rodríguez-Cueto, C., Benito, C., Romero, J., Hernández, M.L., Gómez-Ruiz, M., Fernández-Ruiz, J., Endocannabinoid-hydrolysing enzymes in the post-mortem cerebellum of humans affected by hereditary autosomal dominant ataxias. Pathobiology 81 (2014), 149–159.
41. Romero, J., Hillard, C.J., Calero, M., Rábano, A., Fatty acid amide hydrolase localization in the human central nervous system: an immunohistochemical study. Mol Brain Res 100 (2002), 85–93.
42. Rüb, U., Schöls, L., Paulson, H., Auburger, G., Kermer, P., Jen, J.C., et al. Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7. Prog Neurobiol 104 (2013), 38–66.
43. Seidel, K., Siswanto, S., Brunt, E.R., den Dunnen, W., Korf, H.W., Rüb, U., Brain pathology of spinocerebellar ataxias. Acta Neuropathol 124 (2012), 1–21.
44. Seidel, K., Siswanto, S., Fredrich, M., Bouzrou, M., Brunt, E.R., van Leeuwen, F.W., et al. Polyglutamine aggregation in Huntington's disease and spinocerebellar ataxia type 3: similar mechanisms in aggregate formation. Neuropathol Appl Neurobiol 42 (2016), 153–166.
45. Silva-Fernandes, A., Duarte-Silva, S., Neves-Carvalho, A., Amorim, M., Soares-Cunha, C., Oliveira, P., et al. Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph disease. Neurotherapeutics 11 (2014), 433–449.
46. Soong, B., Cheng, C., Liu, R., Shan, D., Machado-Joseph disease: clinical, molecular, and metabolic characterization in Chinese kindreds. Ann Neurol 41 (1997), 446–452.
47. Stephens, G.J., Does modulation of the endocannabinoid system have potential therapeutic utility in cerebellar ataxia. J Physiol 594 (2016), 4631–4641.
48. Suárez, J., Bermúdez-Silva, F.J., Mackie, K., Ledent, C., Zimmer, A., Cravatt, B.F., et al. Immunohistochemical description of the endogenous cannabinoid system in the rat cerebellum and functionally related nuclei. J Comp Neurol 509 (2008), 400–421.
49. Taniwaki, T., Sakai, T., Kobayashi, T., Kuwabara, Y., Otsuka, M., Ichiya, Y., et al. Positron emission tomography (PET) in Machado-Joseph disease. J Neurol Sci 145 (1997), 63–67.
50. Taroni, F., DiDonato, S., Pathways to motor incoordination: the inherited ataxias. Nat Rev Neurosci 5 (2004), 641–655.
51. 1 receptor-mediated signalling. J Physiol 591 (2013), 3919–3933.